Pharmacist  in aisle of Pharmacy

Proteomimetic Peptide Platform

Proteomimetic peptidic constructs are non-natural self-organizing biomimicking systems. They exhibit similar properties to those of proteins, e.g. they have a tendency to fold into specific periodic compact structures with given biomedical function.
 

Proteomimetic peptidic constructs have biological applications where the tailored 3D structure is crucial.
 

They are a novel class of drug scaffolds with tailored molecular shape and surface.
 

We developed a novel and highly efficient technology (a continuous-flow meso-scale reactor) to synthesize such proteomimetic peptides and their derivatives.
 

The complete characterization of the peptidic construct is routinely performed in our state of the art facilities equipped with LD/CD spectrophotometer, NMR spectrometers, custom-made SAXS, WAXS instruments, FF-TEM, SFG spectroscopy, spectrofluorimeter and HPLC.

Proteomimetic peptidic drugs

Proteomimetic peptidic drug candidates can replace the biological role of the non-functional proteins:

  • Novel, functionally designed peptides with a distinct biological activity such as enzyme inhibition, cell membrane penetration, antiviral or antifungal effect.
     

  • Conjugation with small molecule for desired pharmacological effect, but different mode of action.
     

The proteomimetic peptide conjugate possesses higher biological activity than those of its building blocks.

Proteomimetic peptidic drugs_edited.jpg
Aerial View of Curved Road

Pipeline

EPIPHARMA develops a Peptide IBD In vitro Diagnostic Product and first-in class Proteomimetic Peptide Drugs for patients with major unmet clinical needs.

IBD In vitro Diagnostics

EPI-051

Development Phase

Phase II

Indication

Artificial saliva (Xerostomia)

EPI-031

Development Phase

Pre-clinical

Indication

IN VITRO DIAGNOSTICS & MEDICAL DEVICES
Development Phase
Candidate
Indication
Discovery
Pre-clinical
Phase I
Phase II
Phase III
EPI-051
IBD In vitro Diagnostics
EPI-031
Artificial saliva (Xerostomia)

Antifungal NCE

EPI-024

Development Phase

Pre-clinical

Indication

Anticoagulant NCE

EPI-061

Development Phase

Pre-clinical

Indication

Mitochondrial Ca2+ overload treatment

EPI-041

Development Phase

Discovery

Indication

Cystic fibrosis

EPI-025

Development Phase

Discovery

Indication

DRUGS
Development Phase
Candidate
Indication
Discovery
Pre-clinical
Phase I
Phase II
Phase III
EPI-024
Antifungal NCE
EPI-061
Anticoagulant NCE
EPI-041
Mitochondrial Ca2+ overload treatment
EPI-025
Cystic fibrosis